{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T10:08:05Z","timestamp":1792490885745,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To evaluate survival, efficacy and safety of transarterial chemoembolization (TACE) in the treatment of patients with hepatocellular carcinoma (HCC), through a pooled analysis of patients with BCLC 0, A and B HCC stages, treated with polyethylene glycol drug eluting microspheres (PEG-DEM) TACE.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and Methods<\/jats:title>\n                <jats:p>Patients from 3 retrospective and 2 prospective registries were included. Overall survival (OS), progression-free survival (PFS), tumour response and safety were evaluated. Multivariate Cox regression analysis was performed to evaluate predictors of OS.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 580 patients (72.1% males, mean age 66.9\u2009\u00b1\u200910.3\u00a0years) were included. 43.5% had BCLC A, and 41.0% BCLC B disease stage, and 85.8% were Child\u2013Pugh class A. Complete and partial response (mRECIST or RECIST1.1) were achieved in 60.14% and 27.11% of patients, with overall response and disease control rates of 87.30% and 94.60%, respectively. Median OS was 50.8\u00a0months for the total population, and 61.2 and 38.1\u00a0months for BCLC 0\u2009+\u2009A and BCLC B patients, respectively. Median PFS for the total population, BCLC 0\u2009+\u2009A and BCLC B groups was 15.6, 21.6 and 12.7\u00a0months, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This multicentric pooled analysis confirmed efficacy and safety of PEG-DEM TACE, with a median OS of 50.8\u00a0months.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00270-023-03362-9","type":"journal-article","created":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T00:56:26Z","timestamp":1676076986000},"page":"436-446","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Transarterial Chemoembolization with Anthracyclines-Loaded Polyethylene Glycol Drug Eluting Microspheres for the Treatment of Hepatocellular Carcinoma: A Pooled Multicentric Analysis of Survival in 580 Patients"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1435-4665","authenticated-orcid":false,"given":"Filipe","family":"Veloso Gomes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4556-7663","authenticated-orcid":false,"given":"Thierry","family":"de Ba\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1912-6327","authenticated-orcid":false,"given":"Gontran","family":"Verset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9613-4553","authenticated-orcid":false,"given":"\u00c9lia","family":"Coimbra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4719-0799","authenticated-orcid":false,"given":"Gerardo","family":"Tovar-Felice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1391-0965","authenticated-orcid":false,"given":"Katerina","family":"Malagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9826-0753","authenticated-orcid":false,"given":"Jordi","family":"Bruix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"key":"3362_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"3362_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2021","unstructured":"Reig M, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatology. 2021;76(3):681\u201393.","journal-title":"J Hepatology"},{"key":"3362_CR3","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301\u201314.","journal-title":"Lancet"},{"key":"3362_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatology. 2018;69:182\u2013236.","journal-title":"J Hepatology"},{"key":"3362_CR5","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jhep.2006.10.020","volume":"46","author":"M Varela","year":"2007","unstructured":"Varela M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatology. 2007;46:474\u201381.","journal-title":"J Hepatology"},{"key":"3362_CR6","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s00270-013-0667-2","volume":"37","author":"S Miyayama","year":"2014","unstructured":"Miyayama S, et al. Comparison of local control in transcatheter arterial chemoembolization of hepatocellular carcinoma <\/=6 cm with or without intraprocedural monitoring of the embolized area using cone-beam computed tomography. Cardiovasc Intervent Radiol. 2014;37:388\u201395.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3362_CR7","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s11604-012-0088-1","volume":"30","author":"K Yamakado","year":"2012","unstructured":"Yamakado K, et al. Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis? Jpn J Radiol. 2012;30:560\u20136.","journal-title":"Jpn J Radiol"},{"key":"3362_CR8","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.jvir.2016.05.015","volume":"27","author":"T de Baere","year":"2016","unstructured":"de Baere T, et al. An in vitro evaluation of four types of drug-eluting microspheres loaded with doxorubicin. J Vasc Interv Radiol. 2016;27:1425\u201331.","journal-title":"J Vasc Interv Radiol"},{"key":"3362_CR9","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.3390\/cancers12113405","volume":"12","author":"T de Baere","year":"2020","unstructured":"de Baere T, et al. Real life prospective evaluation of new drug-eluting platform for chemoembolization of patients with hepatocellular carcinoma: PARIS registry. Cancers (Basel). 2020;12:3405.","journal-title":"Cancers (Basel)"},{"key":"3362_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.20344\/amp.8976","volume":"31","author":"M Lima","year":"2018","unstructured":"Lima M, et al. Risk Factors for the Development of Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma Treatment. Acta Med Port. 2018;31:22\u20139.","journal-title":"Acta Med Port"},{"key":"3362_CR11","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jvir.2018.02.004","volume":"29","author":"F Veloso Gomes","year":"2018","unstructured":"Veloso Gomes F, et al. Chemoembolization of hepatocellular carcinoma with drug-eluting polyethylene glycol embolic agents: single-center retrospective analysis in 302 patients. J Vasc Interv Radiol. 2018;29:841\u20139.","journal-title":"J Vasc Interv Radiol"},{"key":"3362_CR12","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.jvir.2017.07.020","volume":"28","author":"C Aliberti","year":"2017","unstructured":"Aliberti C, et al. Transarterial chemoembolization with small drug-eluting beads in patients with hepatocellular carcinoma: experience from a cohort of 421 patients at an italian center. J Vasc Interv Radiol. 2017;28:1495\u2013502.","journal-title":"J Vasc Interv Radiol"},{"key":"3362_CR13","doi-asserted-by":"publisher","first-page":"HEP38","DOI":"10.2217\/hep-2020-0035","volume":"8","author":"G Tovar-Felice","year":"2021","unstructured":"Tovar-Felice G, et al. Unresectable hepatocellular carcinoma treatment with doxorubicin-eluting polyethylene glycol microspheres: a single-center experience. Hepat Oncol. 2021;8:HEP38.","journal-title":"Hepat Oncol"},{"issue":"7","key":"3362_CR14","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.jvir.2021.11.019","volume":"33","author":"K Malagari","year":"2022","unstructured":"Malagari K, et al. Polyethylene-glycol drug-eluting embolic microspheres loaded with doxorubicin for the treatment of hepatocellular carcinoma: feasibility safety and pharmacokinetic study. J Vasc Interv Radiol. 2022;33(7):752\u201361.","journal-title":"J Vasc Interv Radiol"},{"issue":"Suppl 4","key":"3362_CR15","doi-asserted-by":"publisher","first-page":"iv24","DOI":"10.1093\/annonc\/mdw333.24","volume":"27","author":"G Fiorentini","year":"2016","unstructured":"Fiorentini G, et al. B24 Hepatic arterial infusion of Polythylene Glycol drug-eluting beads for Primary liver cancer therapy. Ann Oncol. 2016;27(Suppl 4):iv24.","journal-title":"Ann Oncol"},{"key":"3362_CR16","doi-asserted-by":"publisher","first-page":"430","DOI":"10.2214\/AJR.16.17477","volume":"209","author":"C Aliberti","year":"2017","unstructured":"Aliberti C, et al. Chemoembolization adopting polyethylene glycol drug-eluting embolics loaded with doxorubicin for the treatment of hepatocellular carcinoma. AJR Am J Roentgenol. 2017;209:430\u20134.","journal-title":"AJR Am J Roentgenol"},{"key":"3362_CR17","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00270-019-02192-y","volume":"42","author":"P Lucatelli","year":"2019","unstructured":"Lucatelli P, et al. Balloon-occluded transcatheter arterial chemoembolization (b-TACE) for hepatocellular carcinoma performed with polyethylene-glycol epirubicin-loaded drug-eluting embolics: safety and preliminary results. Cardiovasc Intervent Radiol. 2019;42:853\u201362.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3362_CR18","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s00270-011-0287-7","volume":"35","author":"R Lencioni","year":"2012","unstructured":"Lencioni R, et al. Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol. 2012;35:980\u20135.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3362_CR19","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/hep.24670","volume":"54","author":"J Bruix","year":"2011","unstructured":"Bruix J, et al. Clinical decision making and research in hepato-cellular carcinoma: pivotal role of imaging techniques. Hepatology. 2011;54:2238\u20132234.","journal-title":"Hepatology"},{"key":"3362_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","volume":"10","author":"V Mazzaferro","year":"2009","unstructured":"Mazzaferro V, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35\u201343.","journal-title":"Lancet Oncol"},{"key":"3362_CR21","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1002\/hep.27290","volume":"60","author":"M Kudo","year":"2014","unstructured":"Kudo M, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. Hepatology. 2014;60:1697\u2013707.","journal-title":"Hepatology"},{"key":"3362_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S2468-1253(17)30290-X","volume":"3","author":"M Kudo","year":"2018","unstructured":"Kudo M, et al. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet Gastroenterol Hepatol. 2018;3:37\u201346.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3362_CR23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S2468-1253(17)30156-5","volume":"2","author":"T Meyer","year":"2017","unstructured":"Meyer T, et al. Sorafenib in com-bination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2:565\u201375.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3362_CR24","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","volume":"69","author":"M Kudo","year":"2020","unstructured":"Kudo M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69:1492\u2013501.","journal-title":"Gut"},{"key":"3362_CR25","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.jhep.2021.01.033","volume":"74","author":"J Bruix","year":"2021","unstructured":"Bruix J. Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot. J Hepatol. 2021;74:1483\u20138.","journal-title":"J Hepatol"},{"key":"3362_CR26","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41575-019-0179-x","volume":"16","author":"J Bruix","year":"2019","unstructured":"Bruix J, et al. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2019;16:617\u201330.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3362_CR27","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1148\/radiol.11110282","volume":"262","author":"JH Shim","year":"2012","unstructured":"Shim JH, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology. 2012;262:708\u201318.","journal-title":"Radiology"},{"key":"3362_CR28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/bjc.2014.199","volume":"111","author":"R Golfieri","year":"2014","unstructured":"Golfieri R, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111:255\u201364.","journal-title":"Br J Cancer"},{"key":"3362_CR29","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","volume":"64","author":"R Lencioni","year":"2016","unstructured":"Lencioni R, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatology. 2016;64:1090\u20138.","journal-title":"J Hepatology"},{"key":"3362_CR30","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","volume":"18","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18:293\u2013313.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"3362_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/hep.31424","volume":"73","author":"R Kloeckner","year":"2021","unstructured":"Kloeckner R, et al. Local and Regional Therapies for Hepatocellular Carcinoma. Hepatology. 2021;73(Suppl 1):137\u201349.","journal-title":"Hepatology"},{"key":"3362_CR32","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00330-016-4488-y","volume":"27","author":"A Monier","year":"2017","unstructured":"Monier A, et al. Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion. Eur Radiol. 2017;27:1431\u20139.","journal-title":"Eur Radiol"},{"key":"3362_CR33","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.jhep.2011.09.012","volume":"56","author":"B Guiu","year":"2012","unstructured":"Guiu B, et al. Liver\/biliary injuries following chemoembolisation of endocrine tumors and hepatocellular carcinoma lipiodol vs. drug-eluting beads. J Hepatol. 2012;56:609\u201317.","journal-title":"J Hepatol"},{"key":"3362_CR34","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/tri.13123","volume":"31","author":"HC Pommergaard","year":"2018","unstructured":"Pommergaard HC, et al. Locoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. Transpl Int. 2018;31:531\u20139.","journal-title":"Transpl Int"},{"key":"3362_CR35","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s00270-011-0224-9","volume":"35","author":"S Takaki","year":"2012","unstructured":"Takaki S, et al. Long-term outcome of transcatheter subsegmental and segmental arterial chemoemobolization using lipiodol for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2012;35:544\u201354.","journal-title":"Cardiovasc Intervent Radiol"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-023-03362-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-023-03362-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-023-03362-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T15:05:14Z","timestamp":1680102314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-023-03362-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["3362"],"URL":"https:\/\/doi.org\/10.1007\/s00270-023-03362-9","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]},"assertion":[{"value":"8 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Filipe Veloso Gomes has received research grants from Terumo; educational grants from Terumo, Medtronic, Guerbet; speaker honoraria from Bayer, Guerbet, Medtronic, Roche. Thierry-de-Baere has received consulting fees from Astra-Zeneca, Boston-Scientific, Guerbet, Medtronic and Terumo. Gontran Verset has received honoraria for lectures from Terumo, BTG, Bayer. \u00c9lia Coimbra\u2014no conflicts of interest Gerardo Tovar-Felice has received a research grant from Terumo. Katerina Malagari has received honoraria for lectures from Merit Medical, BTG, Boston Scientific, Terumo. Jordi Bruix has received consulting fees from AbbVie, Adaptimmune, Arqule, Astra-Medimmune, Basilea, Bayer-Shering Pharma, Bio-Alliance, BMS, BTG- Biocompatibles, Eisai, Gilead, Incyte, Ipsen, Kowa, Lilly, MSD, Nerviano, Novartis, Polaris, Quirem, Roche, Sirtex, Sanofi, Terumo; honararia for lectures from Bayer, Eisai, BTG\/Boston Scientific, Sirtex, Terumo, Ipsen, Astra-Zeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Lisbon, Portugal: Ethics Committee Nova medical School\/Faculdade de Cie\u00eancias M\u00e9dicas 36\/2017\/CEFCM Veloso Gomes, F.; Oliveira, J.A.; Tom\u00e9 Correia, M.; Vasco Costa, N.; Abrantes, J.; Torres, D.; Pereira, P.; Ferreira, A.I.; Luz, J.H.; Spaepen, E.; Bilhim, T.; Coimbra E. Chemoembolization of Hepatocellular Carcinoma with Drug-Eluting Polyethylene Glycol Embolic Agents: Single-Center Retrospective Analysis in 302 Patients. <i>J Vasc Interv Radiol <\/i>2018, <i>29<\/i>, 841-849. . Paris, France: Ethics Committee Erasmus University Hospitals ULB \/ Comit\u00e9 d\u2019Ethique hospitalo-facultaire Erasme ULB (Brussels) \u2013 P2017\/233 Ethics Committee University Hospitals St. Luc UCL \/ Comit\u00e9 d\u2019Ethique hospitalo-facultaire Saint-Luc UCL (Brussels) \u2013 T127E2 de Baere, T.; Guiu, B.; Ronot, M.; Chevallier, P.; Sergent, G.; Tancredi, I.; Tselikas, L.; Dioguardi Burgio, M.; Raynaud, L.; Deschamps, F.; Verset, G. Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry. <i>Cancers (Basel) <\/i>2020, 12, 3405. . Athens, Greece: PK Doxorubicin study: Cantonal Committee of Ethics of Research on Human Being (Lausanne) \u2013 460\/15 Hellenic Republic Ministry of Health National Ethics Committee (Athens) \u2013 115\/15 South-Mediterranean II Ethics Committee \/ Comit\u00e9 de Protection des Personnes Sud-M\u00e9diterran\u00e9e II (Marseille) \u2013 215 R15 Ethics Committee for Clinical Investigation Barcelona University Hospitals (Barcelona) \u2013 HCB\/2015\/0689 Malagari et al. Polyethylene-glycol drug-eluting embolic microspheres loaded with doxorubicin for the treatment of hepatocellular carcinoma: feasibility, safety and pharmacokinetic study. <i>JVIR <\/i>2021, <i>provisionally accepted <\/i>Badalona, Spain \u2013 IRB exemption as per local policy: Tovar-Felice, G.; Garcia-Gamez, A.; Benito-Santamaria, V.; Balaguer-Paniagua, D.; Villalba-Au\u00f1on, J.; Sampere-Moragues, J. Unresectable hepatocellular carcinoma treatment with doxorubicin-eluting polyethylene glycol microspheres: a single-center experience. <i>Hepat Oncol<\/i>. 2021, <i>8<\/i>, HEP38.  Brussels., Belgium - IRB exemption as per local policy: Retrospective single-center study of 105 patients \u2013 Retrospective registry from Dr. Gontran Verset. - Not yet published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}